Shots:

• The P-III HELP (Hereditary Angioedema Long-term Prophylaxis) study involves assessing of Takhzyro (300/150 mg- SC) (lanadelumab) vs PBO in 125 patients with HAE attacks for 26 weeks aged 12 years and older
• The P-III HELP result: reduction in mean monthly attack rate 80.1% ; fewer severe attacks (7.4% vs. 22%); HAE attack-free (48.1% vs 7.3%); attacks requiring acute treatment (74% vs 87%); moderate or severe attacks (70% to 83%)
• Takhzyro is a mAb produced using Chinese Hamster Ovary (CHO) cells by recombinant DNA technology and decreases plasma kallikrein activity. Takhzyro 300mg has received FDA’s approval as prophylaxis for the prevention of HAE attacks in patients aged 12 years and older

Ref: Takeda | Image:Takeda